Key result
PPARgamma activators troglitazone and 15d-PGJ2 significantly inhibited mechanical strain-induced cardiac myocyte enlargement (-72%, P<0.0005 and -88%, P<0.0002, respectively).
Why the study?
Do PPARgamma activators inhibit cardiac hypertrophy in neonatal rat cardiac myocytes?
Do PPARgamma activators inhibit cardiac hypertrophy in neonatal rat cardiac myocytes?
PPARgamma activators inhibit mechanically and neurohormonally induced cardiac hypertrophy in neonatal rat myocytes, potentially via the NF-kappaB pathway.
Answers are grounded in this paper and cite their sources.
PPARγ activation may blunt myocyte hypertrophy in vitro; hypothesis-generating in neonatal rat models, no clinical implications yet.
BACKGROUND: Peroxisome proliferator-activated receptors (PPARs) are transcription factors belonging to the nuclear receptor superfamily. PPARgamma mRNA is present in cardiac myocytes; however, whether PPARgamma affects cardiac hypertrophy remains unknown. METHODS AND RESULTS: We investigated the effects of PPARgamma activators on cardiac hypertrophy in neonatal rat cardiac myocytes. Cyclic 4% biaxial mechanical strain caused enlargement of cardiac myocytes (1.3-fold versus control, P<0.0001), but the PPARgamma activators troglitazone and 15-deoxy-Delta(12-14)-prostaglandin J(2) (15d-PGJ(2)) (10 micromol/L) inhibited this effect (troglitazone, -72%, P<0.0005; 15d-PGJ(2), -88%, P<0.0002). Total cell protein was increased by mechanical strain (control, 164.3 microgram/dish; strain, 265.5, P<0.0002), and this effect was inhibited by troglitazone and 15d-PGJ(2) (troglitazone, -61%, P<0.005; 15d-PGJ(2), -72%, P<0.001). [(3)H]Leucine uptake was also increased by mechanical strain (1.9-fold versus control, P<0.002), and this increase was inhibited by troglitazone and 15d-PGJ(2) (troglitazone, -52% at 10 micromol/L, P<0.01; 15d-PGJ(2), -70% at 10 micromol/L, P<0.005). An increase in [(3)H]leucine uptake induced by angiotensin II or phenylephrine was significantly inhibited by troglitazone and 15d-PGJ(2). Mechanical strain induced mRNA expression for brain natriuretic peptide, but PPARgamma activators inhibited this induction. Furthermore, PPARgamma activators inhibited mechanically induced activation of nuclear factor (NF)-kappaB. Pyrrolidine dithiocarbamate, an inhibitor of NF-kappaB activation, inhibited strain-induced [(3)H]leucine uptake (-50% at 100 micromol/L, P<0.05). CONCLUSIONS: These results demonstrate that PPARgamma activators inhibit cardiac hypertrophy in cardiac myocytes and suggest that PPARgamma activators may regulate cardiomyocyte hypertrophy at least partially through the NF-kappaB pathway.
No takes yet. Share an insight, caveat, or question.
Yamamoto et al. (2001) studied Cardiac hypertrophy. PPARgamma activators (troglitazone and 15d-PGJ2) vs. Control (mechanical strain without activators) was evaluated on Enlargement of cardiac myocytes (p=<0.0005). PPARgamma activators troglitazone and 15d-PGJ2 significantly inhibited mechanical strain-induced cardiac myocyte enlargement (-72%, P<0.0005 and -88%, P<0.0002, respectively).
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: